Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial

摘要: Background Only limited data from large randomized clinical trials have been published on the long-term performance of second-generation drug-eluting stents in bifurcation lesions. Methods We investigated patients TWENTE trial safety and efficacy treating lesions with 2 widely applied stents, zotarolimus-eluting Resolute stent (Medtronic Inc, Santa Rosa, CA) everolimus-eluting Xience V (Abbott Vascular, Clara, CA). Three-year follow-up was available 99.3%. Patients were categorized into treatment for ≥1 lesion versus nonbifurcation only. Results Among 1,391 trial, 362 (26%) treated lesions. At 3-year follow-up, target-vessel failure did not differ between (13.1% vs 12.6%; P = .84), whereas periprocedural myocardial infarction rate higher (6.9% 3.1%; < .01). Of treatment, 179 (49.4%) 183 (50.6%) V. There no significant difference groups (13.6% .78), their incidence definite-or-probable thrombosis low similar (1.1% 0.5%, respectively; .62). Conclusion Despite a infarction, outcome after implantation favorable without In addition, we observed stents. Percutaneous coronary interventions (PCIs) associated an increased procedural risk restenosis rate.1 The introduction first generation (DES) reduced restenosis.2, 3 4 Meanwhile, DES more biocompatible, durable polymer-based coatings developed, such as Both are applied, they shown results population all-comer patients5 6 broad patient trial.7, 8 9 lesions, need repeat revascularization, compared first-generation DES.10, 11 12 that exclusively used recently reported very 2-year population.13 Nevertheless, so far, only lesions.13, 14 15 Therefore, present substudy trial,7, 16 performed analysis to compare bifurcated target lesion. evaluate potential between-stent differences,